Diagnostic efficacy of electron microscopy and pleural effusion cytology for the distinction of pleural mesothelioma and lung adenocarcinoma

References

• Travis WDBE, Müller-Hermelink HK, Harris CC. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. International Agency for Research on Cancer ( IARC), Lyon, 2004.
   Google Scholar
• Delgermaa V, Takahashi K, Park EK, et al. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull. World Health Organiz 2011;89:716–724, 724A–724C.
   Google Scholar
• Pasetto R, Comba P, Marconi A. Mesothelioma associated with environmental exposures. La Medicina del lavoro, 2005;96:330–337.
   PubMedGoogle Scholar
• Magnani C, Ivaldi C, Botta M, et al. Pleural malignant mesothelioma and environmental asbestos exposure in Casale Monferrato, Piedmont. Preliminary analysis of a case-control study. La Medicina del lavoro 1997;88:302–309.
   PubMedGoogle Scholar
• Seer.cancer.gov. Age adjusted incidence of mesothelioma all ages (SEER-13). Surveillance E, and End Results Program. (ed.), Bethesda, MD [ database on the Internet] 2015.
   Google Scholar
• Arrieta O, Medina LA, Estrada-Lobato E, et al. First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: Phase II trial. Br J Cancer 2012;106:1027–1032.
   PubMed Web of Science ®Google Scholar
• Arrieta O, Medina LA, Estrada-Lobato E, et al. High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with (99 m)Tc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin. Cancer Chemother Pharmacol 2014;74:211–215.
   PubMed Web of Science ®Google Scholar
• Zhang W, Wu X, Wu L, et al. Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma. Ann Transl. Med. 2015;3:182.
   PubMed Web of Science ®Google Scholar
• Arrieta O, Lopez-Macias D, Mendoza-Garcia VO, et al. A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma. Cancer Chemother Pharmacol 2014;73:975–982.
   PubMed Web of Science ®Google Scholar
• Hammar SP. Macroscopic, histologic, histochemical, immunohistochemical, and ultrastructural features of mesothelioma. Ultrastructural Pathol 2006;30:3–17.
   PubMed Web of Science ®Google Scholar
• Dejmek A. Methods to improve the diagnostic accuracy of malignant mesothelioma. Respir Med 1996;90:191–199.
   PubMed Web of Science ®Google Scholar
• Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: A comparative study. Mod Pathol 2006;19:417–428.
   PubMed Web of Science ®Google Scholar
• Whitaker D. The cytology of malignant mesothelioma. Cytopathol 2000;11:139–151.
   PubMed Web of Science ®Google Scholar
• Sheaff M. Should cytology be an acceptable means of diagnosing malignant mesothelioma? Cytopathol 2011;22:3–4.
   PubMed Web of Science ®Google Scholar
• Smith M, Colby T. The diagnosis of thoracic malignant mesothelioma: Practical considerations and recent developments. Turk patoloji dergisi 2014;30:1–10.
   PubMedGoogle Scholar
• Ordonez NG: Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: A review and update. Hum Pathol 2013;44:1–19.
   PubMed Web of Science ®Google Scholar
• Husain AN, Colby T, Ordonez N, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2013;137:647–667.
   PubMed Web of Science ®Google Scholar
• Oury TD, Hammar SP, Roggli VL. Ultrastructural features of diffuse malignant mesotheliomas. Hum Pathol 1998;29:1382–1392.
   PubMed Web of Science ®Google Scholar
• Sheibani K, Shin SS, Kezirian J, et al. Ber-EP4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma versus adenocarcinoma. Am J Surg Pathol 1991;15:779–784.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: An immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol 2003;27:150–158.
   PubMed Web of Science ®Google Scholar
• Kent M, Rice D, Flores R. Diagnosis, staging, and surgical treatment of malignant pleural mesothelioma. Curr Treat Options Oncol 2008;9:158–170.
   PubMed Web of Science ®Google Scholar
• Betta PG, Andrion A, Donna A, et al. Malignant mesothelioma of the pleura. The reproducibility of the immunohistological diagnosis. Pathol Res Pract 1997;193:759–765.
   PubMed Web of Science ®Google Scholar
• Ordonez NGMB. The roles of immunohistochemistry and electron microscopy in distinguishing epithelial mesothelioma of the pleura from adenocarcinoma. Adv Anat Pathol 1996;3:273–293.
   Google Scholar
• Oczypok EA, Oury TD. Electron microscopy remains the gold standard for the diagnosis of epithelial malignant mesothelioma: A case study. Ultrastructural Pathol 2015;39:153–158.
   PubMed Web of Science ®Google Scholar
• Pereira TC, Saad RS, Liu Y, et al. The diagnosis of malignancy in effusion cytology: A pattern recognition approach. Adv Anat Pathol 2006;13:174–184.
   PubMed Web of Science ®Google Scholar
• Kadota K, Suzuki K, Sima CS, et al. Pleomorphic epithelioid diffuse malignant pleural mesothelioma: A clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma. J. Thoracic Oncol 2011;6:896–904.
   PubMed Web of Science ®Google Scholar